Tag: Bioinformatics
Search News
Welcoming Professor Francesca Ciccarelli to the BCI
24th April 2023
Professor Francesca Ciccarelli will be joining Barts Cancer Institute to lead our Centre for Cancer Genomics & Computational Biology.
Read more
BCI researcher part of Strategic Collaboration Agreement with Queen Mary, Envisagenics and Cancer Research Horizons
14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more
OPTIMA: Improving treatment for cancer patients through artificial intelligence
12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more
Dissecting complex biological pathways with machine learning
19th July 2021
We spoke with Group Leader Dr Jun Wang and Postdoctoral Researcher Dr Anthony Anene from Barts Cancer Institute’s Centre for Cancer Genomics & Computational Biology about their most recent publication. Published in Patterns, the paper describes the development of a machine-learning tool called ACSNI that can be used to predict tissue-specific pathway components from large biological datasets.
Read more
SNPnexus in the fight against COVID-19
8th February 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have released a web-based tool called SNPnexus COVID to streamline the analysis of host genetic sequencing data and allow for the identification and prioritisation of genetic variants that may impact an individual’s susceptibility to and the severity of COVID-19 infection.
Read more
Biological clues in tissues surrounding breast tumours
9th September 2020
A new study has identified molecular characteristics in ‘normal-looking’ tissues surrounding breast tumours that may indicate whether breast cancer is likely to return following surgical removal of the tumour.
Read more